A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymph
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or co
| Condition(s) | Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma |
|---|---|
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Summary | Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib. |
| Who can participate | Inclusion Criteria: * Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are: * receiving study intervention * in the short-term follow-up period, or * in the long-term follow-up period Exclusion Criteria: * Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001 |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Eli Lilly and Company |
| Locations | Miami, Florida, United States; Sarasota, Florida, United States; Atlanta, Georgia, United States; Chicago, Illinois, United States; Boston, Massachusetts, United States; Rochester, Minnesota, United States (+30 more sites) |
| Start date | 2025-05-20 |
| NCT ID | NCT06876662 |
| Official listing | https://clinicaltrials.gov/study/NCT06876662 |